Fiber Lowers Two Uremic Toxins in CKD—But Outcomes Unknown

Fiber supplements can lower two gut-derived uremic toxins in chronic kidney disease (CKD), according to a 2025 review of randomized trials. That is useful biochemical evidence, especially because indoxyl sulfate (IS) and p-cresyl sulfate (pCS) have been linked with cardiovascular risk. It does not yet show that fiber prevents heart attacks, slows kidney decline, or extends life.

The distinction matters. CKD nutrition advice often gets flattened into a list of foods to avoid, while the average reported fiber intake in CKD is about 5.1 g per day. Yet trials have tested 6 to 50 g per day of supplemental fiber. The gap between those numbers is real; the evidence needed to turn it into a universal treatment recommendation is not.

What the pooled trials found

A 2025 systematic review and meta-analysis by Wathanavasin et al. combined 21 randomized controlled trials involving 700 people with CKD: 299 who were not dialysis-dependent and 401 receiving dialysis. The interventions included resistant oligosaccharides, resistant starch, non-starch polysaccharides, and mixed fiber products, given for four to 16 weeks.

Across 11 trials with 398 participants, fiber reduced IS by a standardized mean difference (SMD) of −0.34 (95% confidence interval [CI], −0.57 to −0.12; I²=19.9%). It also reduced pCS by SMD −0.22 (95% CI, −0.42 to −0.02; p=0.03; I²=0%). The review rated both findings GRADE High certainty, largely because trial results were statistically consistent.

That consistency deserves attention, but it needs the right interpretation. An SMD expresses a difference in standard-deviation units, not a patient-friendly absolute change in toxin concentration. The trials measured biomarkers over weeks, not clinical events over years. High GRADE certainty for these pooled biomarker estimates does not mean every individual trial was methodologically pristine: eight of the 21 trials had high risk of bias under the Cochrane RoB2 tool, and the review rated overall bias as moderate.

The biological explanation fits the findings. Gut bacteria can metabolize tryptophan and tyrosine into indole and p-cresol, precursors that the body converts into IS and pCS. Fermentable fiber may shift colonic metabolism toward carbohydrate fermentation and away from this protein-related pathway. A prior 2022 meta-analysis of microbiota-directed therapies also found that approaches such as prebiotics, probiotics, and synbiotics could reduce circulating IS and pCS in CKD. That makes fiber's effect biologically plausible rather than a lone statistical surprise.

Fiber does not lower every toxin or inflammatory marker

The pattern was selective. Fiber did not change trimethylamine N-oxide (TMAO): SMD +0.05, with Very Low GRADE certainty. It also did not produce a reliable reduction in uric acid (SMD −0.18, Very Low certainty) or high-sensitivity C-reactive protein (hs-CRP; SMD −0.01, Very Low certainty). Interleukin-6 did fall, with SMD −0.44 (95% CI, −0.73 to −0.16; p<0.01) and Moderate certainty. Blood urea nitrogen decreased modestly, SMD −0.25 (95% CI, −0.48 to −0.03; I²=21.4%), but that result carried Low certainty.

TMAO’s non-response makes mechanistic sense. Its production begins with microbial conversion of dietary choline and L-carnitine to trimethylamine, a pathway distinct from the tryptophan- and tyrosine-related routes that produce IS and pCS precursors. Fiber may influence several aspects of gut biology, but it is not a universal toxin vacuum cleaner.

Food-based resistant starch may also have a role. A 2021 randomized, double-blind, placebo-controlled crossover trial tested unripe banana flour in people undergoing peritoneal dialysis. The study supports the idea that resistant starch can be delivered as food rather than only as a purified supplement. However, crossover designs require special caution for interventions intended to alter gut microbial activity: a washout period may not fully erase a preceding dietary effect.

The headline weakens in key subgroups

The pCS result differed by trial design. Parallel-group studies showed a significant reduction (SMD −0.37; p<0.01), while crossover studies showed no reduction (SMD +0.06; p=0.71). The interaction between designs was statistically significant (p=0.04). This does not prove that either design is wrong, but it means the overall pCS estimate should not be treated as equally secure in every setting.

Population also mattered. In non-dialysis-dependent CKD, pCS reduction was SMD −0.45 (95% CI, −0.78 to −0.13). In dialysis-dependent CKD, the estimate was SMD −0.08 and non-significant. Dialysis-dependent participants made up 401 of the 700 people in the review, so the uncertainty is not a footnote. It applies to more than half the pooled sample and to a group with especially high illness burden.

The review found no detectable dose-response difference for pCS when trials using 15 g/day or less were compared with those using more than 15 g/day (p for subgroup difference=0.75). That leaves no evidence-based "sweet spot" within the tested 6-to-50-g/day range.

Why resveratrol did not reproduce the result

A 2022 placebo-controlled crossover trial by Alvarenga et al. tested 500 mg/day of trans-resveratrol in 20 non-dialysis CKD patients with a mean estimated GFR of about 34 mL/min. Participants took it for four weeks, followed by an eight-week washout. Resveratrol did not significantly reduce IS, pCS, or indole-3-acetic acid.

The trial also found positive correlations between IS and Nrf2 expression (r=0.24, p=0.03) and between IS and C-reactive protein (r=0.21, p=0.05). Those correlations do not show that resveratrol changed toxin production. They are compatible with its proposed effects on oxidative-stress and inflammatory signaling, which occur downstream of bacterial precursor formation.

Still, a null result in 20 people is not proof that resveratrol can never affect these markers. The review’s fiber-sized effects, roughly SMD 0.22 to 0.34, would require far larger groups—about 175 to 340 participants per arm for 80% power, according to the study’s assessment. The defensible conclusion is narrower: this dose and duration did not lower the measured toxins in this small crossover trial, and pathway-focused supplementation did not substitute for a prebiotic intervention.

Why the biomarkers matter—and why they are not enough

pCS is more than laboratory clutter. A 2026 prospective observational study in patients with ST-elevation myocardial infarction found that pCS independently predicted major adverse cardiovascular events. That association raises the stakes for pCS in CKD, where cardiovascular risk is already high. It does not establish that lowering pCS with fiber will reduce events; observational prediction and treatment benefit are different questions.

No trial in the fiber review reported cardiovascular events, GFR trajectory, hospitalization, or mortality. A 2024 randomized crossover study of a therapeutic diet in hemodialysis patients illustrates that dietary interventions can be tested in dialysis care, but short-term biochemical studies cannot answer long-term outcome questions.

What a cautious CKD patient can take from this

For people with non-dialysis CKD, increasing fermentable fiber is a reasonable discussion to have with a renal dietitian or nephrologist if the specific goal is to reduce IS and pCS. Resistant starch and resistant oligosaccharides were the most frequently studied fiber categories. The evidence supports a biomarker effect, not a promise of kidney rescue.

Advanced CKD requires individualized planning. Higher-fiber foods can also bring potassium and phosphorus, and uremia can make gastrointestinal tolerance difficult. The available trials did not adequately quantify those tradeoffs against toxin reduction. The meta-analysis authors reported that current KDOQI guidance lacks a strong recommendation specifying fiber type, amount, or duration; that guideline status should be confirmed against current primary guidance before making policy claims.

Fiber has the best randomized evidence here for lowering IS and pCS, particularly before dialysis. Resveratrol has no demonstrated benefit for those endpoints at 500 mg/day for four weeks. Neither intervention has shown that it changes the outcomes patients care about most.